Search
Chicago, IL Paid Clinical Trials
A listing of 2029 clinical trials in Chicago, IL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1225 - 1236 of 2029
There are currently 2029 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Offer
Find the Best GLP-1 Weight Loss Providers (2025)
Recruiting
Cutting-edge GLP-1 treatments like semaglutide and tirzepatide are helping thousands lose weight with medically guided support. But with so many online providers, how do you know which programs are trusted, affordable, and right for you?
We reviewed the top GLP-1 brands of 2025 — comparing pricing, prescription process, shipping, pharmacy partners, and real user ratings — to help you find a safe, convenient, and effective path toward your weight-loss goals.
- 100% online programs
- Licensed U.S. clinicians
- Fast shipping & flexible payments
See the rankings & choose the GLP-1 provider that fits your life.
We reviewed the top GLP-1 brands of 2025 — comparing pricing, prescription process, shipping, pharmacy partners, and real user ratings — to help you find a safe, convenient, and effective path toward your weight-loss goals.
- 100% online programs
- Licensed U.S. clinicians
- Fast shipping & flexible payments
See the rankings & choose the GLP-1 provider that fits your life.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Advocate Illinois Masonic Medical Center, Chicago, Illinois
Conditions: Heart Failure
VItamin C in Thermal injuRY: The VICToRY Trial
Recruiting
This study aims to show that giving high dose, intravenous vitamin C in addition to standard care to burned critically ill patients will be associated with less organ dysfunction, improved survival and a quicker rate of recovery. In this study, all patients will receive standard care and of the patients will also receive high dose intravenous vitamin C, while the other half of patients will receive placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: The University of Chicago Medical Center, Chicago, Illinois
Conditions: Shock, Thermal Burn
Olaparib in Patients With HRD Malignant Mesothelioma
Recruiting
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Mesothelioma, Homologous Recombination Deficiency
Diabetes RElated to Acute Pancreatitis and Its Mechanisms
Recruiting
The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and pathophysiology of diabetes mellitus (DM) following acute pancreatitis (AP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: Northwestern University, Chicago, Illinois +1 locations
Conditions: Acute Pancreatitis
Oxytocin Pharmacokinetics and Pharmacodynamics
Recruiting
Oxytocin is the first-line drug to promote contraction of the uterus and prevent atony immediately after delivery. Nonetheless, unpredictable uterine atony refractory to oxytocin affects roughly 250,000 parturients annually in the U.S. and rates are increasing. This two-part study will measure the action of oxytocin at cesarean delivery. The first part will measure the pharmacokinetics of a single intravenous (IV) dose of deuterium-labeled oxytocin. The second part will measure the pharmacodynam... Read More
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/05/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Post Partum Hemorrhage, Cesarean Section Complications, Blood Loss
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
05/05/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois +1 locations
Conditions: Severe Aplastic Anemia
M-Vizion™ Macroscopic Radiographic Study
Recruiting
Study of the patient's subsidence after revision hip arthroplasty by assessing gross stem subsidence in the femoral canal.
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
05/05/2025
Locations: Northwestern Medicine, Chicago, Illinois
Conditions: Revision Hip Arthroplasty
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Recruiting
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: University Chicago Medicine, Chicago, Illinois
Conditions: Locally Advanced Solid Tumor
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
Recruiting
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: aTyr Investigative Site, Chicago, Illinois +2 locations
Conditions: Interstitial Lung Disease
IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)
Recruiting
The scientific premise of this research is that individual, interpersonal, and structural factors impact Black girls' sexual reproductive health outcomes (sexually transmitted infection (STI) and Human Immunodeficiency Virus (HIV)) and experience of sexual violence. This study expands STI/HIV prevention programs to include Black male caregivers, a potentially valuable yet underutilized resource to protect Black girls and reduce their exposure to STI/HIV and sexual violence.
Gender:
ALL
Ages:
14 years and above
Trial Updated:
05/05/2025
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Sexually Transmitted Infections (Not HIV or Hepatitis), HIV Infections, Sexual Behavior
Durometer for Measuring Uterine Tone
Recruiting
This study will evaluate the use of a durometer to measure uterine tone in parturients undergoing cesarean delivery.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/05/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Uterine Tone Disorders, Cesarean Section Complications
Chyme Reinfusion for Type 2 Intestinal Failure
Recruiting
This project aims to introduce and evaluate a novel assistive prosthetic system that helps prevent and treat nutrient and fluid loss from enterocutaneous fistulas. The device system functions simply to return the output from a fistula back into the distal limb of the intestine.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/04/2025
Locations: University Illinois, Chicago, Illinois
Conditions: Intestinal Failure, Enterocutaneous Fistula, Ileostomy - Stoma, High Output Stoma
1225 - 1236 of 2029
